Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Debt: 2014-2021

Historic Total Debt for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Mar 2021 value amounting to $523,000.

  • Lineage Cell Therapeutics' Total Debt was N/A to $523,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $523,000, marking a year-over-year change of. This contributed to the annual value of $523,000 for FY2020, which is N/A change from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Total Debt stood at $523,000 for Q1 2021, which was down 0.00% from $523,000 recorded in Q4 2020.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Debt peaked at $523,000 during Q2 2020, and registered a low of $18,000 during Q4 2017.
  • Its 2-year average for Total Debt is $523,000, with a median of $523,000 in 2021.
  • Data for Lineage Cell Therapeutics' Total Debt shows a maximum YoY slumped of 85.00% (in 2017) over the last 5 years.
  • Lineage Cell Therapeutics' Total Debt (Quarterly) stood at $18,000 in 2017, then followed by $523,000 in 2020, then followed by $523,000 in 2021.
  • Its Total Debt was $523,000 in Q1 2021, compared to $523,000 in Q4 2020 and $523,000 in Q3 2020.